For the past 10 years, the annual 'Antibodies to watch'articles have provided updates on key
events in the late-stage development of antibody therapeutics, such as first regulatory review …

This 2020 installment of the annual 'Antibodies to Watch'series documents the antibody
therapeutics approved in 2019 and in regulatory review in the United States or European …

The pace of antibody therapeutics development accelerated in 2017, and this faster pace is
projected to continue through 2018. Notably, the annual number of antibody therapeutics …

In this 12th annual installment of the Antibodies to Watch article series, we discuss key
events in antibody therapeutics development that occurred in 2020 and forecast events that …

In this 14th installment of the annual Antibodies to Watch article series, we discuss key
events in commercial monoclonal antibody therapeutics development that occurred in 2022 …

Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing
evaluation in late-stage clinical studies, which is expected to drive a trend toward first …

The number of novel antibody therapeutics that received first marketing approvals in 2015
met expectations, with 6 (alirocumab (Praluent®), evolocumab (Repatha®), daratumumab …

The commercial pipeline of recombinant antibody therapeutics is robust and dynamic. As of
early December 2014, a total of 6 such products (vedolizumab, siltuximab, ramucirumab …

ABSTRACT The 'Antibodies to Watch'article series provides an annual summary of
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …

In this 13th annual installment of the annual 'Antibodies to Watch'article series, we discuss
key events in commercial antibody therapeutics development that occurred in 2021 and …